Trials / Completed
CompletedNCT02413229
A Randomized Double Blind Vehicle Controlled Dose Ranging Parallel Design Multiple Site Clinical Study
A Randomized Double Blind Vehicle Controlled Dose Ranging Multiple Site Phase 2 Clinical Study to Evaluate the Efficacy and Safety of DSXS in Patients With Moderate to Severe Scalp Psoriasis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 151 (actual)
- Sponsor
- Sun Pharmaceutical Industries, Inc. · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
The objectives of this study are to evaluate the therapeutic efficacy and safety of DSXS and a Placebo in patients with moderate to severe scalp psoriasis.
Detailed description
This randomized, double-blind, vehicle-controlled, dose-ranging, parallel-group multi-site study is designed to evaluate the therapeutic efficacy and safety of the investigational product, DSXS, for the treatment of moderate to severe scalp psoriasis at different application times up to 30 minutes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DSXS1411 | DSXS (Taro Pharmaceuticals Inc.) |
| DRUG | Placebo | Placebo (vehicle) (Taro Pharmaceuticals Inc.) |
Timeline
- Start date
- 2015-04-01
- Primary completion
- 2015-09-14
- Completion
- 2016-01-29
- First posted
- 2015-04-09
- Last updated
- 2018-12-06
- Results posted
- 2018-12-06
Source: ClinicalTrials.gov record NCT02413229. Inclusion in this directory is not an endorsement.